Tackling metabolic disorders with non-coding RNAs

Resalis Therapeutics is dedicated to developing RNA-based therapies that tackle the root causes of complex metabolic disorders.

With its deep expertise in non-coding RNA and lipid metabolism, Resalis Therapeutics is advancing RES-010 as a safe, effective, and disease-modifying therapy, offering sustained weight loss and improved metabolic health.

With strong preclinical data supporting its development, RES-010 is now entering clinical trials, positioning Resalis Therapeutics as a key company in the evolving landscape of obesity treatment.

Lead Program

RES-010, a non-coding RNA drug candidate designed to treat metabolic diseases.

We applied our deep understanding of metabolic diseases and the ncRNA modality to develop our lead candidate, RES-010. We are advancing RES-010 toward clinical evaluation initially in obesity and fatty liver disease.

Find out more

Meet Us At

Members of our management team will be at:

1st Annual BioPharma Obesity Innovation Forum 2025
January 11, San Francisco
JPM Healthcare Conference 2025
January 13-16, San Francisco

View all events

Corporate Factsheet

Download PDF